[company_age]unknown[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]Monument Therapeutics is a UK-based biotechnology company specializing in the development of precision medicine treatments for serious diseases of the central nervous system (CNS). Founded in 2021 as a spin-out from Cambridge Cognition, Monument Tx leverages its proprietary digital biomarkers to identify patients with homogenous underlying neurobiology and match them with appropriately targeted compounds. This approach aims to reduce heterogeneity and improve treatment outcomes in areas of high unmet need. Monument Therapeutics' precision medicine approach sets it apart from traditional drug development methods, which often target large, heterogeneous patient populations. By focusing on patients with specific biological profiles, Monument Therapeutics aims to develop more effective and well-tolerated treatments for CNS diseases.[/description][ps]Precision medicine treatments for serious CNS diseases[/ps]